0JQ2 Stock Overview
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
KALA BIO, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.83 |
| 52 Week High | US$18.76 |
| 52 Week Low | US$5.27 |
| Beta | -1.84 |
| 1 Month Change | -9.97% |
| 3 Month Change | -13.19% |
| 1 Year Change | -56.56% |
| 3 Year Change | -98.21% |
| 5 Year Change | -98.33% |
| Change since IPO | -99.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JQ2 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -6.1% | -2.3% | -0.7% |
| 1Y | -56.6% | -29.4% | -1.8% |
Return vs Industry: 0JQ2 underperformed the UK Biotechs industry which returned -29.6% over the past year.
Return vs Market: 0JQ2 underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| 0JQ2 volatility | |
|---|---|
| 0JQ2 Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0JQ2's share price has been volatile over the past 3 months.
Volatility Over Time: 0JQ2's weekly volatility has decreased from 14% to 9% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 43 | Mark Iwicki | www.kalarx.com |
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.
KALA BIO, Inc. Fundamentals Summary
| 0JQ2 fundamental statistics | |
|---|---|
| Market cap | US$19.26m |
| Earnings (TTM) | -US$42.20m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs 0JQ2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JQ2 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$42.20m |
| Earnings | -US$42.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 455.6% |
How did 0JQ2 perform over the long term?
See historical performance and comparison